investor relations presentation...2021/01/21 · packaging, with conception -to-launch and turnkey...
TRANSCRIPT
Investor Relations Presentation
January 2021
Forward Looking Statements & Non-GAAP Financial Measures
This presentation includes forward-looking statements. Forward-looking statements are made pursuant to the safe harbor provisions of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 and are based on management’s beliefs and assumptions in light of information currently available to management. Accordingly, the Company’s actual results may differ materially from those expressed or implied in such forward-looking statements due to known or unknown risks and uncertainties that exist in the Company’s operations and business environment, including, among other factors, those described in documents filed by the Company with the Securities and Exchange Commission, specifically its Form 10-Ks and 10-Qs. The Company does not assume any obligation to update, amend or clarify such statements to reflect new events, information or circumstances after the date of this presentation.
During the course of this presentation, certain non-GAAP financial information will be presented.
A reconciliation of those numbers to GAAP financial measures is available on the company’s website at www.aptar.com on the Investor’s page (click on Events & Presentations / Presentations).
2
Overview
3
SALES BY REGION
55%33%
6%
6%
ATTRACTIVE END MARKETS
SERVING BEST KNOWN GLOBAL & LOCAL BRANDS
DIVERSIFIED PORTFOLIO
RESEARCH AND IP-DRIVEN
1,250Patent Families
Approximately3%R & D
Of Annual Revenue
THE LEADER IN CONSUMER DISPENSING AND DRUG DELIVERY
75-year history of innovation
Providing brand differentiation and consumer / patient convenience
Consistent long-term focus, stability and financial results
$2.9 bil*
4
*2019 Annual Revenue
We transform ideas into products and services that transform lives.
Examples of Products Counting on Aptar Drug Delivery and Dispensing Solutions (many are critical during the pandemic)
5
Rescue Drugs and Therapies
Preventive Medicines and Diagnostics Hand Sanitizers
Disinfectants Infant Nutrition
Pantry Staples
Pharma Beauty + Home Food + Beverage
6
Leveraging Deep Industrial and Product Knowhow Globally Across Three Reporting Segments
6* - LTM = Last twelve months ending September 30, 2020; the EBITDA %’s of LTM values are calculated on total Segment Adjusted EBITDA and exclude Corporate Expenses
Common Technologies and Solutions… …Serving Three Market-facing Reporting Segments
Core Manufacturing Technologies1
Best-in-Class Products and Services2
Aimed at Global Megatrends3
Precision Injection Molding
High-Speed Assembly
Metal Processing + Decorating
Material Science/Active Packaging
Dispensing and Delivery
Sealing
Active Packaging
Sustainability
Health + Wellness
Connectivity
Urbanization
Changing Demographics
e-Commerce/Individualization
% of Total LTM* Sales % of Total LTM* EBITDA
41%
45%
14%
68%
21%
11%
35% EBITDA Margin
10% EBITDA Margin
17% EBITDA Margin
$1.2 bil
$1.3 bil
$0.4 bil
$418 mil
$131 mil
$65 mil
YTD 2020 Recap
• Impact of COVID-19 tracking with our expectations from earlier this year: Q2 was low-point, markets generally performing as anticipated, gradual recovery in process
• Best of breed Pharma business continued to grow device and component sales in each market over very strong prior year
• Strong growth in Q2 and Q3 sales to the Personal Care market partially offsetting decreased sales to the Beauty Market
• Good growth in sales to the Food market offsetting decreased sales to the Beverage market
• Recent acquisitions performing well including FusionPKG and Nobel International
• Generating strong level of cash flow above prior year levels
7
Aptar Pharma Advertisement-8%-6%-4%-2%0%2%4%6%8%
10%
Q1 Q2 Q3
Sales Growth by Quarter 2020
Reported Core
Anticipated Pandemic Impact 2020
Pharma Segment
8
Aptar Pharma Today
9
SALES BY REGION (2020)
65%29%
2%
4%
SALES BY MARKET (2020)
45%
23%
20%
12% Prescription
Consumer HealthCareInjectables
Active Packaging
CUSTOMERS (Approx. 3,000)
INNOVATIVE SOLUTIONS
PATENTS
PATIENT / CONSUMER EXPERIENCE
8 BillionOver
Solutions per Year
750Patent Families
Managing close to
Successful long-term track record with over 150 approved NDAs, ANDAs and INDs in
past five years
9
Leader in Delivery Systems for Traditional Therapies
10
Nasal Delivery Solutions Eye Care Delivery Solutions Pulmonary Delivery SolutionsGlobal leader in nasal devices for Allergic Rhinitis, Aptar Pharma delivers across a
wide spectrum of nasal needs, from respiratory and allergy treatments to
vaccines and crisis medications.
Global leader in pressurized metered dose inhaler (pMDI) valves. We address the
Asthma and COPD therapy markets with a broad range of devices including pMDI
valves, Dry Powder Inhalers (DPIs), and electronic and connected devices.
Our Ophthalmic Squeeze Dispenser is the leading device for preservative-free multidose prescription medications and OTC eye care products with over 250
references on the market.
Growth from Drugs Repurposed for New Delivery Formats
Bidose Nasal Spray Device Nasal Unidose DevicesProtective Active Packaging Container and Unidose Powder System Device
11
Recent examples:
Anti-depressant Therapy Hypoglycemic Crisis Treatment Epilepsy Seizure Treatments
Growth in the Injectables Market
12
Proven injectables partner• 450+ customers in 70+ countries
worldwide
• Working with all of the top 10 Pharma players in injectables
• 70 of the 100 top molecules, mostly life saving treatments
COVID-19 Opportunities
• > 100 injectable vaccines / antiviral treatments being explored
• Increase in emergency / antibiotics treatments
• QuickStart™ turnkey solution for clinical development
Added-value solutions to meet most stringent market requirements around the development of complex & highly sensitive drug formulations
• PremiumCoat™
• Premium Fill®
• Premium Vision™
Global manufacturing network expansion to meet fast
growing demand
Expanding Our Pharma Services Platform
13
Foundation for Future Growth: Support through every step of the drug development journey
Guiding you through every step of drug product development
Device & formulation
developmentClinical trials Regulatory
filingsMarket launch &
post-launch
A global leader in patient onboarding and adherence programs.
A leading provider of orally inhaled & nasal drug product design & development services.
A full-service cGMPlab specializing in analytical testing of drug delivery systems.
A full-service cGMP lab providing industry-leading particulate detection & predictive analytical services.
A global provider of innovative drug delivery systems and service solutions.
Aptar Pharma Services
Q3 Segment Recap and New Product LaunchesAptar Pharma• Core sales growth of our devices and primary
components in each end market
• Some tailwinds from COVID-19-related demand for elastomer components
• Flu vaccine demand
• High level of hospitalizations resulting in increase in number of injected medicines
• Some early-stage stopper orders
• Launched AdhereIT™, a connected onboarding solution for patients who use autoinjectors
• Bag-on-valve system and actuator featured on Vicks Sinex™ Saline Ultra Fine Nasal Mist
• Proven unidose nasal system chosen for a new naloxone spray called Ventizolvelaunched in Europe
AdhereIT™
14
Aptar Pharma Advertisement
Growth in Active Packaging Solutions
Glucose Test Strips
EUA Filed April 2020: Introducing ActivShield™ Solution for Virus Mitigation on N95 Masks
16
ActivShield™ strips are 10mm x 10mm x 0.3mm thick
ActivShield™ is a safe and convenient way to deliver antimicrobial & antiviral treatment of N95 masks on site.
ActivShield™ production can quickly ramp to 10 million per week
Aptar Pharma
Q3 2020 Results
(1) Excludes acquisitions and currency effects. (2) Adjusted EBITDA (earnings before net interest, taxes,
depreciation and amortization) excludes restructuring costs, acquisition costs, non-recurring purchase accounting adjustments.
Metric 3 Year Average
Q32020
Long-term Target
Core sales growth1 10% 11% 6-10%
Adj. EBITDA2 margin 35% 36% 32-36%
17
$269$316
$0
$40
$80
$120
$160
$200
$240
$280
$320
$360
Q3 2019 Q3 2020
$ in
milli
ons
Sales
Reported
+17%
Core 11%
Acquisitions 2%
Currency Effects
4%
36% 36%
0%
10%
20%
30%
40%
Q3 2019 Q3 2020
Adjusted EBITDA(2) Margin %
Aptar Pharma
YTD 2020 Results
(1) Excludes acquisitions and currency effects. (2) Adjusted EBITDA (earnings before net interest, taxes,
depreciation and amortization) excludes restructuring costs, acquisition costs, non-recurring purchase accounting adjustments.
Metric 3 Year Average
YTD2020
Long-term Target
Core sales growth1 10% 8% 6-10%
Adj. EBITDA2 margin 35% 36% 32-36%
18
$824$914
$0
$200
$400
$600
$800
$1,000
YTD 2019 YTD 2020
$ in
milli
ons
Sales
Reported
+11%
Core 8%
Acquisitions 3%
Currency Effects
0%
36% 36%
0%
10%
20%
30%
40%
YTD 2019 YTD 2020
Adjusted EBITDA(2) Margin%
Beauty + Home Segment
19
SALES BY REGION (2020)
52%30%
11%
7%
SALES BY MARKET (2020)
46%
46%
8%
Beauty
Personal Care
Home Care
CUSTOMERS (6,000+)
INNOVATIVE SOLUTIONS
PATENTS
CONSUMER EXPERIENCE
16 BillionOver
Solutions per year
400Patent Families
Aptar Beauty + Home Today
Over
A significant amount of Europe sales end up in Asia in luxury and travel
20
Beauty Home Care StaplesPersonal Care EssentialsGlobal leader in the beauty packaging
industry, known for combining functional dispensing with premium aesthetics. We provide solutions for the luxury facial skin care, cosmetic and perfumery markets, as
well as turnkey solutions ideal for indie brands and the fast beauty market.
Providing a wide variety of solutions for liquid soaps, hand sanitizers, sun
protection, hair care products and body lotions. Sustainability is a focus and in
addition to using PCR, Aptar’s pumps are currently being used on refillable personal
care products for TerraCycle’s Loop platform.
Full range of dispensing systems for staples such as surface cleaners and disinfectants, air fresheners, and pet
care.
Broad Portfolio of Brand-differentiating Solutions
21
Strategic Steps to Strengthen Our Beauty Business
22
BTY• Recently acquired a 49% equity
interest in BTY• Leading Chinese manufacturer of high
quality, decorative metal components, metal-plastic sub-assemblies, and complete color cosmetics packaging solutions for the beauty industry
Ongoing Footprint Consolidation• We are closing our Stratford and Torrington
(CT) sites in the US, and our Ballinasloe site in Ireland; will absorb and rationalize production capacities into existing otherfacilities
• Better positions us to serve our customers and focus on long-term, profitable growth
• Continuation of other steps we have made to streamline our Beauty + Home footprint (facility consolidations in India, Argentina and Southeast Asia, and sale of molding facility in the US)
FusionPKG• Recently acquired FusionPKG, leader in high
quality, prestige airless and color cosmetics packaging, with conception-to-launch and turnkey solutions for the North American beauty market
• Proven creativity, engineering, formulation and fast go-to-market capabilities – ‘fast-beauty’
• Existing relationships with both global cosmetic and skin care customers and with many indie brands
• Potential to scale this beyond North America to other regions
Q3 Segment Recap and New Product Launches
Aptar Beauty + Home• Strong demand in the personal care market for
dispensing pumps and closures for hand sanitizers and liquid soaps
• Increased sales to the home care market primarily related to cleaners and disinfectants
• Beauty market continues to be negatively impacted by the effects of COVID-19
• Launched spray pumps and closures for Zest antibacterial sprays and soaps
• Lotion pumps are featured on new antibacterial hand soap for Vaseline® and Life Buoy brands and spray pump found on Colgate® mouth protect
• Spray pumps for new perfume and cologne launches including Tribeca by Bond No. 9®, Tom Ford by Estée Lauder™, Peony Rose by Avon ®
and many others
23
Aptar Beauty + Home
Q3 2020 Results
(1) Excludes acquisitions and currency effects. (2) Adjusted EBITDA (earnings before net interest, taxes,
depreciation and amortization) excludes restructuring costs, acquisition costs, non-recurring purchase accounting
adjustments.
Metric 3 Year Average
Q3 2020
Long-term Target
Core sales growth(1) 3% -5% 3-6%
Adj. EBITDA(2) margin 13% 10% 15-17%
24
$328 $337
$0
$80
$160
$240
$320
$400
Q3 2019 Q3 2020
$ in
milli
ons
Sales
Core -5%
Acquisitions 7%
Currency Effects
1%
Reported
3%13%
10%
0%
4%
8%
12%
16%
Q3 2019 Q3 2020
Adjusted EBITDA(2) Margin %
Aptar Beauty + Home
YTD 2020 Results
(1) Excludes acquisitions and currency effects. (2) Adjusted EBITDA (earnings before net interest, taxes,
depreciation and amortization) excludes restructuring costs, acquisition costs, non-recurring purchase accounting
adjustments.
Metric 3 Year Average
YTD 2020
Long-term Target
Core sales growth(1) 3% -9% 3-6%
Adj. EBITDA(2) margin 13% 10% 15-17%
25
$1,038$962
$0
$200
$400
$600
$800
$1,000
$1,200
YTD 2019 YTD 2020
$ in
milli
ons
Sales
Reported
-7%Core -9%
Acquisitions 4%
Currency Effects
-2%
14%
10%
0%
4%
8%
12%
16%
YTD 2019 YTD 2020
Adjusted EBITDA(2) Margin %
Food + Beverage Segment
26
SALES BY REGION (2020)
28%57%
7%
8%
SALES BY MARKET (2020)
74%
26%Food
Beverage
CUSTOMERS (>200 clients with top 20 representing 65% of sales)
INNOVATIVE SOLUTIONS
PATENTS
CONSUMER EXPERIENCE
Aptar Food + Beverage Today
7 BillionOver
Solutions per Year
150Patent Families
Over
27
Food ProtectionAptar Food + Beverage is setting new standards to improve food safety. Our active packaging technology protects fresh cut produce and fresh seafood from harmful pathogens like bacteria,
fungi and viruses.
On-The-Go BeverageAptar serves the beverage market
by providing closures for sports drinks, drinkable dairy, juices and
bottled water. We reinvent and improve the drinking experience with tethered caps, child-friendly closures and e-commerce ready
solutions.
Fridge and Pantry Staples
Aptar Food + Beverage uses our innovative technologies to reinvent
everyday staples. Our solutions provide product differentiation for customers on the grocery store
shelf and improved functionality for the end user.
Consumer-focused, Value-driven Applications
28
Sustainable and Convenient Solutions
Tethered SolutionsOur tethered solutions improve the recyclability of bottle caps as they
stay connected to the bottle throughout its lifecycle.
Flexible Packaging
As a leader in the development of flexible package dispensing, we are helping
customers increase their market share with innovative, best-in-class pouch fitments (sealing and tamper evidence) and flow-
controlling dispensing solutions.
29
Q3 Segment Recap and New Product LaunchesAptar Food + Beverage• Strong core growth in the food market attributed to
the demand for pantry staples with consumers continuing to dine at home
• Lower sales to the beverage market due to the on-the-go beverage category being affected by the pandemic
• Effects of passing through lower resin prices to customers also affected the segment’s overall growth
• Helped bring to market the limited edition, in-store Big Mac® sauce for McDonalds in Brazil featuring our closure
• Added value to new product launches in the US with closures and SimpliSqueeze® valves including Old El PasoTM taco sauce and a new oral hygiene water enhancer for pets called Tally-Ho by Ocean Spray
30
Aptar Food + Beverage
Q3 2020 Results
(1) Excludes acquisitions and currency effects. (2) Adjusted EBITDA (earnings before net interest, taxes,
depreciation and amortization) excludes restructuring costs, acquisition costs, non-recurring purchase accounting
adjustments.
Metric 3 Year Average
Q3 2020
Long-term Target
Core sales growth(1) 5% 2% 6-10%
Adj. EBITDA(2) Margin 16% 19% 18-21%
31
$104 $106
$0
$20
$40
$60
$80
$100
$120
Q3 2019 Q3 2020
$ in
milli
ons
Sales
Reported
2%
Core 2%
Acquisitions0%
Currency Effects
0%
18% 19%
0%
6%
12%
18%
Q3 2019 Q3 2020
Adjusted EBITDA(2) Margin %
Aptar Food + Beverage
YTD 2020 Results
(1) Excludes acquisitions and currency effects. (2) Adjusted EBITDA (earnings before net interest, taxes,
depreciation and amortization) excludes restructuring costs, acquisition costs, non-recurring purchase accounting
adjustments.
Metric 3 Year Average
YTD 2020
Long-term Target
Core sales growth(1) 5% -5% 6-10%
Adj. EBITDA(2) Margin 16% 18% 18-21%
32
$327$304
$0
$60
$120
$180
$240
$300
$360
YTD 2019 YTD 2020
$ in
milli
ons
Sales
Reported-7%
Core -5%
Acquisitions0%
Currency Effects
-2%
17% 18%
0%
5%
10%
15%
20%
YTD 2019 YTD 2020
Adjusted EBITDA(2) Margin %
Appendix
33
Financial Results
34
Third Quarter 2020 Reported Results
35
Q3 Highlights• Very good quarter that speaks to
the resilience of our broad portfolio and, our diverse and attractive end markets
• Pharma segment reported impressive growth compared to a strong quarter a year ago
• Core sales growth in the food, personal care and home care markets
• Sales to the beauty and beverage markets continue to be impacted by COVID-19 pandemic
+2%Core Sales
Growth*
+2%Currency Effects
+4%Acquisitions
31%Q3 2019Reported
Effective Tax Rate
29%Q3 2020Reported
Effective Tax Rate
$701$759
$0
$200
$400
$600
$800
Q3 2019 Q3 2020
Reported Q3 Sales(in millions $)
+8% $0.85 $0.95
$-
$0.20
$0.40
$0.60
$0.80
$1.00
Q3 2019 Q3 2020
Reported Q3 EPS+12%
* See accompanying slide titled: Forward Looking Statements & Non-GAAP Financial Measures.
Adjustments: • 2019: Restructuring initiatives of $6.0 mil;
transaction costs related to acquisitions of $0.7 mil
• 2020: Restructuring initiatives of $3.4 mil; Transaction costs related to acquisitions of $0.2 mil
* See accompanying slide titled: Forward Looking Statements & Non-GAAP Financial Measures.
Third Quarter 2020 Adjusted EPS and Adjusted EBITDA
36
31%Q3 2019Effective Tax
Rate Adjusted Earnings*
28%Q3 2020Effective Tax
Rate Adjusted Earnings*
Q3 Adjusted EPS and Adjusted EBITDA Highlights
• Strong results of Pharma and Food + Beverage segments drove higher EBITDA and offset weaker results of Beauty + Home
• Continued under-absorption of overhead due to COVID-19, mainly in our beauty facilities
$0.97 $1.00
$- $0.20 $0.40 $0.60 $0.80 $1.00 $1.20
Q3 2019 Q3 2020
Adjusted Q3 EPS*
+3%$146 $157
$0
$50,000
$100,000
$150,000
$200,000
Q3 2019 Q3 2020
Adjusted Q3 EBITDA(in millions $)
+7%
Nine Months Year-to-Date 2020 Reported Results
37
YTD Highlights• Pharma segment continues to perform
well through the first nine months of the year with growth over a very strong period a year ago
• Beauty + Home and Food + Beverage segments experienced a more difficult first nine months due to the impacts of COVID-19
• Progressive signs of improvement for Beauty + Home and positive results for Food + Beverage as we moved further into the year
• Pleased with the performance of our recent acquisitions, in particular FusionPKG and Noble
-2%Core Sales
Growth*
-1%Currency Effects
+3%Acquisitions
29%YTD 2019
Reported Effective Tax
Rate
29%YTD 2020
ReportedEffective Tax
Rate
$2,188 $2,180
$0
$500
$1,000
$1,500
$2,000
$2,500
YTD 2019 YTD 2020
Reported YTD Sales(in millions $)
0%
* See accompanying slide titled: Forward Looking Statements & Non-GAAP Financial Measures.
Adjustments: • 2019: Restructuring initiatives of $17.3 mil;
transaction costs related to acquisitions of $1.8 mil
• 2020: Restructuring initiatives of $15.6 mil; Transaction costs related to acquisitions of $4.8 mil; Purchase accounting adjustments of $1.3 mil
* See accompanying slide titled: Forward Looking Statements & Non-GAAP Financial Measures.
Nine Months Year-to-Date 2020 Adjusted EPS and Adjusted EBITDA
38
29%YTD 2019Effective Tax
Rate Adjusted Earnings*
28%YTD 2020Effective Tax
Rate Adjusted Earnings*
YTD Adjusted EPS and Adjusted EBITDA Highlights• Strong Pharma results able to
compensate for COVID-related shortfalls, especially within our beauty and beverage applications
• Realizing temporary operating inefficiencies in order to maintain critical supply of product during COVID
• Recent acquisitions (CSP Technologies, FusionPKGand Noble) performing well
$461 $437
$0
$100,000
$200,000
$300,000
$400,000
$500,000
YTD 2019 YTD 2020
Adjusted YTD EBITDA(in millions $)
-5%$3.15 $2.72
$-
$1.00
$2.00
$3.00
$4.00
YTD 2019 YTD 2020
Adjusted YTD EPS*
-14%
Outlook
27-29%Q4 expected tax rate range(prior year Q4
Adj. EPS effective tax rate
= 28%)
Outlook Highlights
• We expect to achieve core sales growth in the fourth quarter
• Rising demand in many end markets, expected to offset COVID-19 related declines in other markets
• Expect our Pharma business to continue to do well with traditional business and pandemic-related business
• Capital expenditures estimated range for 2020 is $240 - $250 million
• Depreciation & amortization estimate for 2020 is ~$220M - $225 million
Guidance Fx Euro Rate = 1.17
$0.73$0.84 $0.84 – $0.92
$0.00
$0.20
$0.40
$0.60
$0.80
$1.00
$1.20
Q4 2019Reported
Q4 2019Adjusted*
Q4 2020Outlook
Earnings Per Share
* See accompanying slide titled: Forward Looking Statements & Non-GAAP Financial Measures. 39
Consolidated Financial Targets
40
Metric3 Year
Average 2019 Q3 YTD 2020 Long-term TargetCore sales growth1 5% 3% -2% 4-7%
Adj. EBITDA2 /Sales % 20% 21% 20% 20-22%
ROIC3 13% 11% 10% 13-15%
Dividend Payout Ratio 36% 36% 40% 30-40%
Leverage Ratio ≈ 1.7X ≈ 1.7X ≈ 1.8X 1-3X1 – Excludes acquisitions and currency effects.
2 – Adjusted EBITDA (earnings before net interest, taxes, depreciation and amortization) excludes restructuring costs, acquisition costs, non-recurring purchase accounting adjustments.
3 – Return on invested capital = adjusted earnings before net interest and taxes, less tax effect / average capital (average of beginning of year and end of year capital) [capital = equity plus debt less cash].
4 – Cash dividends paid / adjusted earnings per share.
Strategic Priorities
Macro Trends
• Aging Population• Connectivity
• E-Commerce Supply Chain • Health and Wellness
• Sustainability• Urbanization
• Rise of Eastern Economies• Shareholder Engagement
2017Financial (five year avg)Sales Growth 3%EBITDA Margin 19%
AcquisitionsStrategic technologies in the US and EU
TalentEvolving need for greater capabilities and diversity
Geographic FocusAmericas & EU
Strategic Priorities2022Financial Sales Growth 4-7%EBITDA Margin 20-22%
Acquisitions/PartnersGlobal acquisitions, partnerships, incubators, new business models
TalentGreater diversity, inclusion and global capabilities
Geographic FocusAdded emphasis on Asia/Middle East/Eastern EU
41
3% (2019), -2% (2020 YTD)
Board, EVP General Counsel, CHRO, Asian Leadership, Strategy/ M&A, Innovation, Digital , Diversity Targets
External Benchmarks, Innovation Pipeline, Performance Mgmt, 6σ, Sustainability
Higher Growth, Beauty + Home and Aptar Margin Expansion
CSP Technologies, FusionPKG, BTY, Sonmol, Nanopharm, Reboul, Gateway, Noble, PureCycle, Loop, Nippon Closures
O r g a n i c G r o w t h
T a l e n t & L e a d e r s h i p
E x c e l l e n c e P i l l a r s
T r a n s f o r m a t i o n
A c q u i s i t i o n s & P a r t n e r s h i p s
Compounding Growth Story 2009 - 2019
42
+4.5%CAGR
Core Sales
+8%CAGR
Adjusted EPS
+9%CAGR
Dividend
• average yield over 10 years = 1.6%
• 27 consecutive years of paying increased
annual dividends
Revenue Near-term Sensitivity Related to COVID-19
43
Our Markets % of Revenue* Key Drivers
Pharma 38% Stable across most medicines and categories; Most prescription drugs and OTC products are easily available for delivery; Potential upside should injectable treatments be developed / grow.
Home Care 4% Stable across most categories; Potential upside with increased demand for cleaners.
Food 10% Major categories such as Condiments, Dairy and Infant Nutrition are stable; Food Service (certain closures and trays) negatively impacted by confinement and restaurant closings.
Personal Care 19% Major categories such as Grooming (including Haircare, Shaving) and Sunscreens are negatively impacted by confinement; Partially offset by higher demand for sanitizers and soaps.
Beverage 5% Majority of Beverage business is related to on-the-go beverages, including functional beverages and premium bottled water, all negatively impacted from confinement.
Beauty 24% Prestige and Mass Beauty products significantly impacted by reduced travel (travel retail sales), confinement and store closings (less usage, less opportunity to purchase and e-commerce volumes not offsetting retail product sales declines).
Q1: Crisis Early Stage
Q2: Crisis Low Point H2: Gradual Recovery
Mag
nitu
de o
f Im
pact
Least Affected
Most Affected
* Based on 2019 annual sales
Free Cash Flow and Capital Allocation
44
Highlights• Balance sheet remains strong and we have
generated more cash flow in the first nine months of 2020 than in the prior year, primarily due to improvements in working capital
• We have a consistent balanced capital allocation strategy
• Temporarily paused our share repurchasing program as a precautionary measure given near-term uncertainties
• Capital expenditures estimated range for 2020 is $220 - $240 million
• Depreciation & amortization estimate for 2020 is $220 - $230 million
$194 $208
$0
$50
$100
$150
$200
$250
YTD 2019 YTD 2020
YTD Free Cash Flow(in millions $)
ESG
45
New in 2020
“Most Responsible Companies in France”
#48up from
#79
Merck (17), P&G (23), Apple (44), BD (46), Ball (65)
_____________________________________
Dupont (121), Estee Lauder (136), Dow (230), Eastmen (232), Alcoa(256), Westrock (257), Walmart
(263), Sonoco (293), PepsiCo (318)
270 A Listed out of 5,600+ scored
Danone, HP, L’Oreal, Apple, AZ, Bayer, Braskem, Coca-Cola,
Colgate-Palmolive, Estee Lauder, General Mills, GSK, J&J, Mars McCormick, Owens, PepsiCo, TetraPak, Unilever, Walmart
1 of 4 industry leaders on Prime Index
Ball (B-)BBillerudKorsnäs AB (B-)
SIG Combibloc Group AG (C+)
#83up from
#196
Climate:
A up from B-
Water:
B up from C-
C+up from
C-
??from 68
Platinum = top 1% of respondents
Other companies TBD
46
Ball (16), Colgate-Palmolive (26), Coca-Cola (44)
_____________________________________
Starbucks (49), West Pharma (54), McCormick (55), Sonoco (64),
P&G (72)
Recent Accolades
Stock Closure Portfolio (PCR)
Designed to Recycle Mono Material
Post Consumer Recycled (Food grade)Circular Economy
Sustainable Solutions and Ventures
47
Exploring connected refillable solutions
Diversity and Inclusion
• ATR included in the SPDR® SSGA Gender Diversity Index ETF (SHE)
• Board of Directors comprised of 40% Women Directors
• Director Maritza Montiel named One of the 15 Most Influential Hispanic Leaders by Latino Leaders
• sHero Award for Best Place to Work for Female Executives in China
• Partnering with Catalyst organization
• Workplace Survey focused on career advancement, job satisfaction, diversity and leadership
48
Matt DellaMariaSVP, Investor Relations & Communications
Phone: 815-479-5530Email: [email protected]
49